Objectives-To investigate ultrasonographic features of focal nodular hyperplasia of the liver with contrast-enhanced ultrasonography (CEUS) using Sonazoid (perflubutane; GE Healthcare, Oslo, Norway).
F ocal nodular hyperplasia is the second most common type of benign liver tumor and accounts for approximately 8% of all primary hepatic tumors. 1 It is thought to be a hyperplastic response to increased blood flow in an arterial malformation rather than a true neoplasm. 2 Focal nodular hyperplasia affects more women than men and is more frequently found in young women. Approximately 20% of patients have multiple masses. Histologically, focal nodular hyperplasia is composed of benignappearing hepatocytes, occurs in a histologically normal or nearly normal liver, and contains a variable number of Kupffer cells. They are separated by fibrous septa that often form typical stellate central scars. 3, 4 These fibrous septa contain a large, thick-walled artery and a rich network of capillaries, which is responsible for the hypervascular nature of most focal nodular hyperplasia lesions seen on imaging. Radiologically, focal nodular hyperplasia is characterized by arterial-phase hypervascularity on contrast-enhanced imaging. Thus, differentiation of focal nodular hyperplasia from other hypervascular liver masses, including hepatocellular carcinoma and hepatocellular adenoma, has received attention in the imaging literature. [5] [6] [7] Contrast-enhanced ultrasonography (CEUS) is widely accepted and has improved the diagnostic performance of radiologists examining focal hepatic tumors, including focal nodular hyperplasia. 8, 9 Secondgeneration contrast agents currently used in CEUS are microbubbles composed of low-solubility gas encapsulated by a phospholipid shell, such as SonoVue (sulfur hexafluoride; Bracco SpA, Milan, Italy), Definity (perflutren lipid; Lantheus Medical Imaging, North Billerica, MA), and Sonazoid (perflubutane; GE Healthcare, Oslo, Norway), and facilitate acquisition of a real-time scan using low-mechanical index imaging. Among these, Sonazoid is taken up by Kupffer cells in the reticuloendothelial system of the liver and persists for several hours. 10 Therefore, it has typical behavior that leads to 2 phases of contrast enhancement: a vascular phase and a postvascular or Kupffer phase. The most prominent advantage of Sonazoid is that Kupffer-phase images can improve the diagnostic sensitivity of hepatic malignancy because Kupffer cells are absent in most hepatic neoplasms, especially malignant tumors.
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Recent studies [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] have reported that CEUS can provide valuable information about the central feeding artery, spoked-wheel vascularity, and the centrifugal filling pattern of focal nodular hyperplasia, which can lead to a confident diagnosis. However, most studies have been conducted with a contrast agent other than Sonazoid. Because the reticuloendothelial system is intact in focal nodular hyperplasia, CEUS with Sonazoid may provide a diagnostic advantage over other contrast agents for accurately diagnosing this disease. To the best of our knowledge, few reports have focused on CEUS findings in focal nodular hyperplasia using Sonazoid, and the number of focal nodular hyperplasia lesions that have been evaluated is small. 19, 22 Therefore, the purpose of this study was to investigate CEUS of focal nodular hyperplasia using Sonazoid and to assess its Kupfferphase enhancement pattern.
Materials and Methods

Patients
The Institutional Review Board of the Samsung Medical Center approved this retrospective study and waived the requirement for written informed consent from participants. We identified 602 consecutive patients who had undergone CEUS using Sonazoid to evaluate focal hepatic tumors detected by conventional ultrasonography (US), computed tomography (CT), or magnetic resonance imaging (MRI) between July 2012 and February 2015 at our institution. Among these, we recruited study populations from our CEUS database based on the following inclusion criteria: (1) they underwent CEUS for suspected focal nodular hyperplasia in previous radiologic imaging studies; (2) they had no history of viral hepatitis or liver cirrhosis; (3) video clips of CEUS were available; and (4) results were confirmed by histologic analysis or follow-up imaging sets, with data available providing pathologic confirmation or consistent imaging features on follow-up imaging studies conducted more than 1 year later, including CEUS, CT, and MRI. Finally, 31 patients were selected for inclusion in our study. Among them, 1 patient had multiple hepatic nodules (>5), and focal nodular hyperplasia was suspected. Because we were unable to evaluate the dynamic vascular enhancement patterns for multiple hepatic lesions, we performed CEUS for only 1 dominant hepatic lesion suspected to be focal nodular hyperplasia. Therefore, 31 nodules in 31 patients were included in our study.
A diagnosis of focal nodular hyperplasia was established on the basis of histologic confirmation (n 5 4) or typical imaging findings from either contrast-enhanced MRI or dynamic contrast-enhanced CT (n 5 27), which was performed within 1 month before or after CEUS. Typical imaging findings were homogeneous and intense enhancement with a spoked-wheel pattern during the arterial phase, isoattenuation or isointensity during the portal venous and late dynamic phases, and accumulation of gadolinium chelates within the central area on delayed contrast-enhanced T1-weighted MRI. Additionally, consistent imaging features of the lesion on followup image sets after at least 1 year were also considered as diagnostic criteria.
Contrast-Enhanced US Technique
All CEUS examinations were performed by faculty-level abdominal radiologists (H.K.L. and W.K.J.), who each had at least 5 years of clinical experience with CEUS in daily clinical practice. Before applying CEUS, grayscale US was conducted to identify a target lesion with a LOGIC E9 US system (GE Healthcare, Waukesha, WI) equipped with a 1-5-MHz convex transducer. If the lesion was small or inconspicuous and CT or MRI of the patient was available, fusion imaging (volume navigation; GE Healthcare) from the same US machine was performed. Color Doppler US was also performed to detect intratumoral vessels. Contrast-enhanced US was performed after grayscale US scanning, using the same transducer and US machine. The imaging approach used in this study was previously published by our institution. 23 We used the contrast harmonic imaging technique with a default mechanical index setting of 0.24. The liver was scanned at 15 frames per second. The beam focus was located in the posterior margin of the liver. Sonazoid was used at a dose of 0.015 mL/kg and administered by a manual bolus injection, followed by a flush with 10 mL of normal saline via a peripheral venous line in the left forearm. Intermittent CEUS images were obtained during the following 4 phases: arterial (10-40 seconds after injection of Sonazoid), portal venous (60-90 seconds), delayed (3 minutes), and Kupffer (>10 minutes). If the target lesion was not identified during the arterial phase, the same amount of Sonazoid was reinjected after evaluation during the Kupffer phase. All phases were recorded as video clips. Some representative images, especially during the arterial and Kupffer phases, were captured after CEUS and sent to a picture archiving and communication system (Centricity Radiology RA 1000; GE Healthcare, Chicago, IL).
Image Analysis
We evaluated grayscale, color Doppler, and CEUS image sets. Three experienced radiologists (H.K.L., W.K.J., and J.L.) retrospectively reviewed all CEUS images, including video clips on a picture archiving and communication system monitor and achieved consensus. Readers were blinded to the final diagnosis as well as to clinical histories and other imaging findings. The locations of liver lesions were recorded according to the Couinaud classification system, and the size of each lesion was measured on the picture archiving and communication system monitor. The depth and baseline echogenicity of the lesions, determined by grayscale US (hyperechoic, isoechoic, or hypoechoic), were also recorded. We evaluated the echogenicity of background liver parenchyma for each patient. A color Doppler study was conducted to determine tumor vascularity.
We focused on vascular and enhancement patterns during the arterial, portal venous, delayed, and Kupffer phases on CEUS. To determine the characteristic lesion features, we defined 3 focal nodular hyperplasia imaging findings based on studies conducted by Wang et al 15 and Luo et al. 19 "Central artery" and "stellate vascularity" were defined by the presence of enhanced central arteries with a spoked-wheel or starlike pattern. A "centrifugal filling pattern" was defined as initial central enhancement that progressed to the periphery of the lesion over time. Finally, a "perfusion defect" during the Kupffer phase was a nodule or area that appeared hypoechoic compared with background hepatic parenchyma during that phase. We correlated focal nodular hyperplasia vascular patterns during the arterial phase based on lesion size. The enhancement pattern during the dynamic phase (hyperenhancement, isoenhancement, or hypoenhancement) was also recorded.
Results
The 31 patients in the study included 12 men and 19 women (age range, 21-82 years; mean, 47 years). The mean diameter of the tumors 6 SD, as measured by grayscale US, was 2.2 6 0.9 cm (range, 1.0-4.0 cm). The lesion locations included the right hepatic lobe in 19 patients (segment 8 in 6, segment 5 in 4, segment 7 in 3, and segment 6 in 6), the left hepatic lobe (lateral segment in 6 patients and segment 4 in 5), and the caudate lobe in 1 patient. All lesions were found within 10 cm of the skin surface. On grayscale images, focal nodular hyperplasia was hypoechoic in 16 of 31 lesions (51.6%), isoechoic in 11 (35.5%), and hyperechoic in 4 (12.9%) compared with adjacent liver parenchyma. Twenty-one lesions (67.7%) were found in normal livers on US; the remaining 10 lesions (32.3%) were located in fatty liver: 8 in mild and 2 in moderate fatty liver. When the liver was nonsteatotic, focal nodular hyperplasia lesions were mostly isoechoic, but 4 of 21 lesions (19.0 %) were considered homogeneously hyperechoic. When steatosis was present, the lesions were more often hypoechoic than isoechoic, and none of the lesions were considered hyperechoic ( (Figure 1) . At least 1 sign was visible in 26 of 31 lesions (83.9%), whereas 5 (16.1%) did not show any of these signs on CEUS. The vascular patterns of the 31 lesions during the arterial phase, correlated with lesion size, are shown in Table 2 .
Twenty-six of the 31 lesions (83.9%) were hyperenhanced to various degrees in comparison with adjacent liver parenchyma during the late arterial phase. During the portal venous and delayed phases, 29 lesions (93.5%) were either isoechoic or slightly hyperechoic compared with the surrounding liver parenchyma. Two lesions (6.5%) appeared hypoechoic throughout the vascular and Kupffer phases (Figure 2 ). Lesion enhancement was observed in various patterns during the dynamic scans in the late arterial, portal venous, delayed, and Kupffer phases. The most common 4 Table 3 .
Discussion
In this study, 23 of 31 focal nodular hyperplasia lesions (74.2%) showed typical vascular patterns, including central stellate vascularity and centrifugal enhancement. These typical vascular patterns on CEUS have been well documented in previous studies, with a wide range of detection rates from 30% to 100%. [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] Among these studies, Luo et al 19 reported sensitivity of 82% for "diffuse enhancement with spoked-wheel arteries" with Sonazoid, using intermittent scanning with a high mechanical index. The centrifugal filling pattern was detected in 80.6% (25 of 31) of the lesions in this study. Wang et al 15 described this sign as the only independent factor for predicting focal nodular hyperplasia lesions that measured 3 cm or less and reported a detection rate of 65.8%.
When a US contrast agent is used, focal nodular hyperplasia can be diagnosed with high confidence because the contrast agent can help show real-time fine blood flow within the tumor, using nonlinear continuous imaging modes at a low mechanical index. However, previous studies reported these characteristic features in other hepatic tumors, including hepatocellular carcinoma, and metastasis, 15, 19 and even focal nodular hyperplasia did not show any typical vascular patterns. Therefore, a dynamic enhancement study provides valuable information for diagnosing focal nodular hyperplasia. The typical enhancement pattern of focal nodular hyperplasia on CEUS is generally accepted as homogeneous hyperenhancement during the arterial phase and sustained hyperenhancement or isoenhancement compared with the surrounding liver during the portal venous and delayed phases. 15, 18, 24 In this study, the most common enhancement pattern was hyperenhancement during the arterial phase and isoenhancement during the portal venous and delayed phases (21 of 31 [67.7%]), which was in agreement with previous results. However, some authors reported an atypical enhancement pattern for focal nodular hyperplasia, using second-generation contrast agents such as SonoVue and Definity; negative enhancement of the lesion compared with the liver was observed during the portal and delayed phases. Bertin et al 13 reported that late-phase wash-out was observed in 5.3% of lesions. In a study by Wang et al, 15 hypoenhancement of lesions during the portal and delayed phases was observed in 21.2% and 30.6%, respectively. In addition, 17.6% of the lesions showed a typical malignant enhancement pattern of "hyper, hypo, and hypo." This atypical enhancement pattern was thought to be caused by the presence of the central scar, severe fatty changes in the underlying liver, or true focal nodular hyperplasia wash-out.
We used Sonazoid as the contrast agent in this study; it consists of stable perflubutane-based microbubbles. As these microbubbles are phagocytosed by reticuloendothelial cells (Kupffer cells) in the liver, 10, 19, 22 this contrast agent can provide liver parenchymal enhancement for an extended period, referred to as the Kupffer phase, which is extremely stable and robust enough for multiple scans. Multiple studies suggest that the Kupffer phase can differentiate hepatic malignancy from benign hepatic lesions. 11, 25 Most malignant lesions generally lack Kupffer cells 26 and are detected as a hypoechoic area during the Kupffer phase, 9, 10 although, in the case of well-differentiated hepatocellular carcinoma, 20% to 30% of the lesions can show isoechogenicity during the Kupffer phase 27, 28 because most well-differentiated hepatocellular carcinomas contain Kupffer cells that are similar in number as in surrounding nontumorous tissues. 26 We assumed that focal nodular hyperplasia has Kupffer cells in the intact reticuloendothelial system; therefore, CEUS with Sonazoid could help diagnose focal nodular hyperplasia, especially if typical vascular patterns are not visible on CEUS. In our study, 5 of the 31 lesions (16.1%) did not show any characteristic vascular patterns on early arterial-phase images. Among these, 4 lesions showed isoenhancement or hyperenhancement during the dynamic phases and Kupffer phase, which could lead to a diagnosis of focal nodular hyperplasia. To date, few studies have reported Kupffer-phase findings of focal nodular hyperplasia. According to one study, 10 all focal nodular hyperplasia lesions (n 5 4) in the series showed no Kupffer-phase defects (ie, isoenhancement or hyperenhancement). In contrast, Shibasaki et al 25 reported a case of focal nodular hyperplasia that had visible defects during the Kupffer phase. They suggested a relationship between the presence of a central scar and hypoenhancement of focal nodular hyperplasia during the Kupffer phase. In our study, 2 focal nodular hyperplasia cases (6.5%) appeared as hypoenhanced lesions throughout the dynamic and Kupffer phases. A large central scar was visible in 1 of 2 lesions on MRI. The other did not show a definite central scar. We suggest that the reason the central scar was not visible on MRI was due to the small size of the lesion, which was approximately 1 cm.
In our study, baseline color Doppler US showed greater sensitivity than CEUS in detecting the feeding central artery (88% versus 77.4%, respectively); this result was supported by Bartolotta et al. 18 This finding could be explained by the possibility of searching the artery approaching the focal nodular hyperplasia without the time constraints of color Doppler US.
There were several limitations to our study. First, the retrospective character of data collection and review may have included a selection bias. Second, in most focal nodular hyperplasia cases, especially 2 cases that appeared hypoechoic on the Kupffer-phase analysis, the final diagnosis was established without histopathologic confirmation. However, ethical concerns made it impossible to perform histopathologic examinations of all benign liver tumors. Therefore, we applied strict diagnostic criteria in these cases, including typical findings of focal nodular hyperplasia on MRI as well as interval stability for at least 1 year; however, this approach could have increased the likelihood of a selection bias. Therefore, additional studies are needed to analyze correlations between pathologic and imaging findings. Third, the consensus reading prevented us from performing an interobserver analysis. However, previous studies have already reported good interobserver agreement, at rates greater than moderate degrees, for CEUS features of focal nodular hyperplasia. 13, 15, 18 In conclusion, CEUS with Sonazoid can provide valuable hemodynamic information, including the vascular pattern and Kupffer-phase imaging, of focal nodular hyperplasia, which can enhance diagnostic confidence and provide an effective approach for follow-up in clinical practice.
